ReShape Lifesciences, Inc. - RSLS STOCK NEWS

ReShape Lifesciences (Nasdaq: RSLS) will present a live company overview at VirtualInvestorConferences.com on December 16, 2021, at 2:00 pm ET. CEO Bart Bandy and CFO Tom Stankovich invite investors to participate and ask questions in real-time. An archived webcast will be available for those unable to attend live. Attendees are encouraged to pre-register and complete an online system check. ReShape Lifesciences focuses on weight loss and metabolic health solutions, including the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System.

ReShape Lifesciences Inc. (NASDAQ:RSLS) announced the success of its national advertising campaign and Virtual Media Tour, achieving key performance indicators and exceeding expectations.
In the first five weeks, scheduled patient consults rose by 520%, indicating strong market response. The Lap-Band, a minimally invasive weight-loss solution, is FDA-approved and widely reimbursed. The campaign aims to address obesity, exacerbated by the Covid pandemic, with engaging patient testimonials to resonate with consumers. Ads will now run on additional platforms, enhancing visibility.

ReShape Lifesciences (RSLS) reported Q3 2021 revenue of $3.7 million, a 2.9% increase year-over-year, with a 29.2% revenue growth for the nine-month period. The company launched a national marketing campaign and expanded its product line with new supplements. However, operating expenses surged to $17.1 million due to significant one-time costs, including $10.7 million in stock-based compensation. G&A expenses reached $12 million, reflecting merger-related costs. Despite these challenges, cash and cash equivalents stood at $29.3 million as of September 30, 2021.

ReShape Lifesciences (NASDAQ:RSLS) will report its third quarter 2021 financial and operational results on November 11, 2021, at 8:30 a.m. ET. A webinar discussing these results will be available at 8:45 a.m. ET on the same day, accessible via the Investor Relations page of the ReShape website.

The company focuses on weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System. ReShape also provides a virtual weight-management program and an online wellness marketplace.

ReShape Lifesciences (NASDAQ:RSLS) has launched ReShape Optimize™, a new line of supplements tailored for bariatric surgery and weight loss patients, in collaboration with ProCare Health. This expansion seeks to meet the increasing demand for quality supplementation that addresses nutritional deficiencies. Over 195 million U.S. adults take dietary supplements, and the ReShape Optimize line includes multivitamins, probiotics, calcium, and protein supplements. The products will be available on the ReShape Marketplace™, enhancing the company’s comprehensive offerings in the weight loss sector.

ReShape Lifesciences (NASDAQ:RSLS) will be represented by Thomas Stankovich, Chief Financial Officer, at the 6th Annual Dawson James Small Cap Growth Conference on October 21, 2021. The event will take place at the Wyndham Grand Hotel in Jupiter, Florida, and Stankovich's presentation is slated for 2:25 p.m. ET. He will discuss the company's business operations and value creation in its weight-loss product portfolio. Interested investors can schedule one-on-one meetings through their Dawson James contact or Daniel Kontoh-Boateng at The Ruth Group.

ReShape Lifesciences (NASDAQ: RSLS) has launched a comprehensive advertising campaign to promote its Next-Generation Lap-Band Program, aiming to increase patient demand. This multi-platform initiative includes national television ads on popular channels and print advertisements in major consumer publications. The campaign responds to the significant rise in obesity, projected to affect nearly half the adult population by 2030. ReShape's goal is to build brand awareness and drive procedural volumes, leveraging data from historical marketing efforts.

ReShape Lifesciences (NASDAQ:RSLS) was featured in BioTuesdays, highlighting its role in addressing obesity-related health issues. CEO Bart Bandy emphasized the company's comprehensive approach to weight loss solutions, differentiating from competitors focused on single therapies. Their lead product, Lap-Band®, has over 1 million placements globally, offering a minimally invasive option for obesity treatment. ReShape aims to support patients through various products, including the investigational ReShape Vest™ and the virtual reshape™ program, targeting the growing health crisis of obesity and metabolic diseases.

ReShape Lifesciences (NASDAQ:RSLS) will exhibit at the 17th Annual Bariatric Summit in Washington, D.C., on September 18-19, 2021. Heather Mackie, Director of reshapecare™, will present during key patient care sessions. The summit aims to foster discussions among healthcare professionals on obesity-related conditions and integrated weight loss solutions. ReShape's exhibit opens at 9:25 AM ET on September 18. Mackie will cover topics including vitamin deficiencies post-surgery and nutritional guidance.